Garrett M. Frampton

43.5k citations

219 papers · 15.6k indexed · 6 hit papers · h-index 55

Molecular Biology top 0.5%
Oncology top 0.2%
Cancer Research top 0.2%
Pulmonary and Respiratory Medicine top 0.5%
Immunology top 1%

Co-authors: Richard A. Young Vincent A. Miller Philip J. Stephens Rudolf Jaenisch Aaron M. Goodman Razelle Kurzrock Phillip A. Sharp Albert W. Cheng
Topics: Cancer Genomics and Diagnostics (124 papers)Lung Cancer Treatments and Mutations (51 papers)Cancer Immunotherapy and Biomarkers (43 papers)
Cited by: Cancer Research Oncology Molecular Biology
Journals: Nature Cell Proceedings of the National Academy of Sciences
Partner nations: United States France Italy

In The Last Decade

Garrett M. Frampton

209 papers receiving 15.5k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Histone H3K27ac separates active from poised enhancers and predicts developmental state

2010 2.9k citations Garrett M. Frampton et al. profile →
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers

2017 1.6k citations Aaron M. Goodman, Shumei Kato et al. Molecular Cancer Therapeutics profile →
Connecting microRNA Genes to the Core Transcriptional Regulatory Circuitry of Embryonic Stem Cells

2008 1.1k citations Garrett M. Frampton et al. profile →
Foxp3 occupancy and regulation of key target genes during T-cell stimulation

2007 580 citations Garrett M. Frampton et al. profile →
PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers

2019 386 citations Mark Yarchoan, Lee A. Albacker et al. JCI Insight profile →
Integrative Analysis of a Large Real-World Cohort of Small Cell Lung Cancer Identifies Distinct Genetic Subtypes and Insights into Histologic Transformation

2023 75 citations Meagan Montesion, Justin Y. Newberg et al. Cancer Discovery profile →

Peers

Countries citing papers authored by Garrett M. Frampton

Since Specialization

Citations

This map shows the geographic impact of Garrett M. Frampton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Garrett M. Frampton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Garrett M. Frampton more than expected).

Fields of papers citing papers by Garrett M. Frampton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Garrett M. Frampton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Garrett M. Frampton. The network helps show where Garrett M. Frampton may publish in the future.

Co-authorship network of co-authors of Garrett M. Frampton

This figure shows the co-authorship network connecting the top 25 collaborators of Garrett M. Frampton. A scholar is included among the top collaborators of Garrett M. Frampton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Garrett M. Frampton. Garrett M. Frampton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Association between ancestry and tumor somatic mutations in a large national cohort of women with breast cancer 2025 ·npj Breast Cancer ·Kirkpatrick B. Fergus,Justin Y. Newberg,(unknown),Laura Fejerman,Luis G. Carvajal‐Carmona,Eric A. Collisson,Niharika Dixit,Garrett M. Frampton,Franklin W. Huang,(unknown),Elad Ziv	0
2	Meta-analysis reveals differences in somatic alterations by genetic ancestry across common cancers 2025 ·Nature Genetics ·(unknown),Amy Xie,(unknown),Kelly R. Pekala,(unknown),(unknown),(unknown),Kanika Arora,Walid K. Chatila,Andriy Derkach,Ronglai Shen,Garrett M. Frampton,Michael F. Berger,Nikolaus Schultz,Justin Y. Newberg,Jian Carrot‐Zhang	0
3	Comprehensive characterization of PTEN mutational profile in a series of 34,129 colorectal cancers 2022 ·Nature Communications ·Ilya G. Serebriiskii,(unknown),Rossella Tricarico,(unknown),Émmanuelle Nicolas,Mitchell I. Parker,Justin Y. Newberg,Garrett M. Frampton,Joshua E. Meyer,Erica A. Golemis	31
4	Tumor Fraction Correlates With Detection of Actionable Variants Across > 23,000 Circulating Tumor DNA Samples 2022 ·JCO Precision Oncology ·Hatim Husain,Dean C. Pavlick,Bernard J. Fendler,Russell W. Madison,Brennan Decker,Ole Gjoerup,Christine A. Parachoniak,(unknown),Rachel Erlich,Alexa B. Schrock,Garrett M. Frampton,Meghna Das Thakur,Geoffrey R. Oxnard,Hanna Tukachinsky	58
5	High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-Naïve Patients with Diverse Cancers 2020 ·Molecular Cancer Therapeutics ·Paul Riviere,Aaron M. Goodman,Ryosuke Okamura,Donald A. Barkauskas,(unknown),Suzanna Lee,Noor Khalid,(unknown),(unknown),Garrett M. Frampton,David Fabrizio,Andrew B. Sharabi,Shumei Kato,Razelle Kurzrock	53
6	Genomic Profiling of Prostate Cancers from Men with African and European Ancestry 2020 ·Clinical Cancer Research ·Yusuke Koga,Hanbing Song,Zachary R. Chalmers,Justin Y. Newberg,Eejung Kim,Jian Carrot‐Zhang,(unknown),Paz Polak,Sarki A. Abdulkadir,Elad Ziv,Matthew Meyerson,Garrett M. Frampton,Joshua D. Campbell,Franklin W. Huang	58
7	Relationship between tumor mutational burden and maximum standardized uptake value in 2-[18F]FDG PET (positron emission tomography) scan in cancer patients 2020 ·EJNMMI Research ·Amin Haghighat Jahromi,Donald A. Barkauskas,Matthew Zabel,Aaron M. Goodman,Garrett M. Frampton,Mina Nikanjam,Carl K. Hoh,Razelle Kurzrock	10
8	Comprehensive Genomic Landscapes in Early and Later Onset Colorectal Cancer 2019 ·Clinical Cancer Research ·Christopher H. Lieu,Erica A. Golemis,Ilya G. Serebriiskii,Justin Y. Newberg,Amanda Hemmerich,Caitlin Connelly,Wells A. Messersmith,Cathy Eng,S. Gail Eckhardt,Garrett M. Frampton,Matthew Cooke,Joshua E. Meyer	135
9	Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy 2019 ·Cancer Immunology Research ·Aaron M. Goodman,Ethan S. Sokol,Garrett M. Frampton,Scott M. Lippman,Razelle Kurzrock	202
10	Abstract 1599: Determining patient ancestry based on targeted tumor comprehensive genomic profiling 2019 ·Cancer Research ·Justin Y. Newberg,Caitlin Connelly,Garrett M. Frampton	17
11	Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence 2019 ·The Oncologist ·Samuel J. Klempner,David Fabrizio,Shalmali Bane,Marcia Reinhart,Tim Peoples,Siraj M. Ali,Ethan S. Sokol,Garrett M. Frampton,Alexa B. Schrock,Rachel Anhorn,Prasanth Reddy	243
12	Comprehensive characterization of RAS mutations in colon and rectal cancers in old and young patients 2019 ·Nature Communications ·Ilya G. Serebriiskii,Caitlin Connelly,Garrett M. Frampton,Justin Y. Newberg,Matthew Cooke,V. A. Miller,Siraj M. Ali,Jeffrey S. Ross,Elizabeth A. Handorf,Sanjeevani Arora,Christopher H. Lieu,Erica A. Golemis,Joshua E. Meyer	149
13	The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy 2019 ·Clinical Cancer Research ·Todd C. Knepper,Meagan Montesion,Jeffery S. Russell,Ethan S. Sokol,Garrett M. Frampton,Vincent A. Miller,Lee A. Albacker,Howard L. McLeod,Zeynep Eroglu,Nikhil I. Khushalani,Vernon K. Sondak,Jane L. Messina,Michael J. Schell,James A. DeCaprio,Kenneth Y. Tsai,Andrew S. Brohl	111
14	PD-L1 expression and tumor mutational burden are independent biomarkers in most cancersbreakdown → 2019 ·JCI Insight ·Mark Yarchoan,Lee A. Albacker,Alexander C. Hopkins,Meagan Montesion,Karthikeyan Murugesan,Teena Vithayathil,Neeha Zaidi,Nilofer S. Azad,Daniel A. Laheru,Garrett M. Frampton,Elizabeth M. Jaffee	386
15	Successful Treatment of HIV-Associated Kaposi Sarcoma with Immune Checkpoint Blockade 2018 ·Cancer Immunology Research ·Natalie Galanina,Aaron M. Goodman,Philip R Cohen,Garrett M. Frampton,Razelle Kurzrock	84
16	Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancersbreakdown → 2017 ·Molecular Cancer Therapeutics ·Aaron M. Goodman,Shumei Kato,Lyudmila Bazhenova,Sandip Pravin Patel,Garrett M. Frampton,Vincent A. Miller,Philip J. Stephens,Gregory A. Daniels,Razelle Kurzrock	1638
17	High-Throughput Genomic Profiling of Adult Solid Tumors Reveals Novel Insights into Cancer Pathogenesis 2017 ·Cancer Research ·Ryan J. Hartmaier,Lee A. Albacker,Juliann Chmielecki,Mark Bailey,Jie He,Michael E. Goldberg,Shakti Ramkissoon,James Suh,Julia A. Elvin,(unknown),Garrett M. Frampton,Jeffrey S. Ross,Vincent A. Miller,Philip J. Stephens,Doron Lipson	85
18	BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy 2017 ·Pigment Cell & Melanoma Research ·Douglas B. Johnson,(unknown),Zachary R. Chalmers,Garrett M. Frampton,Siraj M. Ali,Samuel M. Rubinstein,David Fabrizio,Jeffrey S. Ross,Sohail Balasubramanian,Vincent A. Miller,Philip J. Stephens,Jeffrey A. Sosman,Christine M. Lovly	28
19	Concordance of Genomic Alterations between Primary and Recurrent Breast Cancer 2014 ·Molecular Cancer Therapeutics ·Funda Meric‐Bernstam,Garrett M. Frampton,Jaime Ferrer-Lozano,Roman Yelensky,José Alejandro Pérez Fidalgo,Ying Wang,Gary A. Palmer,Jeffrey S. Ross,Vincent A. Miller,Xiaoping Su,Pîlar Eroles,Juan Antonio Barrera,Octavio Burgués,Aňa Lluch,Xiaofeng Zheng,Ayşegül Şahin,Philip J. Stephens,Gordon B. Mills,Maureen Cronin,Ana M. González-Angulo	68
20	Comprehensive Genomic Profiling of Pancreatic Acinar Cell Carcinomas Identifies Recurrent RAF Fusions and Frequent Inactivation of DNA Repair Genes 2014 ·Cancer Discovery ·Juliann Chmielecki,Katherine E. Hutchinson,Garrett M. Frampton,Zachary R. Chalmers,Adrienne Johnson,Chanjuan Shi,Julia A. Elvin,Siraj M. Ali,Jeffrey S. Ross,Olca Baştürk,Sohail Balasubramanian,Doron Lipson,Roman Yelensky,William Pao,Vincent A. Miller,David S. Klimstra,Philip J. Stephens	126

About Garrett M. Frampton

Garrett M. Frampton is a scholar working on Cancer Research, Oncology and Pathology and Forensic Medicine, having authored 219 papers that have together received 15.6k indexed citations. Recurring topics across this work include Cancer Genomics and Diagnostics (124 papers), Lung Cancer Treatments and Mutations (51 papers) and Cancer Immunotherapy and Biomarkers (43 papers). The work is most often cited by research in Cancer Research (4.0k citations), Oncology (5.9k citations) and Molecular Biology (8.2k citations). Garrett M. Frampton has collaborated with scholars based in United States, France and Italy. Frequent co-authors include Richard A. Young, Vincent A. Miller, Philip J. Stephens, Rudolf Jaenisch, Aaron M. Goodman, Razelle Kurzrock, Phillip A. Sharp, Albert W. Cheng, G. Grant Welstead and Jacob H. Hanna. Their work appears in journals such as Nature, Cell and Proceedings of the National Academy of Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact